

Registration opens for SMi's 4th Annual Ophthalmic Drugs Conference

SMi reports: Registration is now open for the 4th annual Ophthalmic Drugs Conference, taking place in London on the 23rd-24th November 2020.

LONDON, UNITED KINGDOM, June 25, 2020 /EINPresswire.com/ -- SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd-24th of November 2020, in London.

The global ophthalmic drug market is forecast to surpass \$60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy.



With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

The newly-released brochure with the three-day agenda and full speaker line-up is available to download online at www.ophthalmicdrugs.com/pr1ein

As Europe's leading Ophthalmic Drugs conference, the conference will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.

Chair For 2020:

•Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals

Featured 2020 Speakers Include:

- •Magali Taiel, Chief Medical Officer, Gensight-Biologics
- •Alan Franklin, CEO, Forward Vue Pharma
- •Brian Levy, CEO, Ocunexus Therapeutics
- •Mictor Chong, Global Medical Head, Retinal Health, Boehringer Ingelheim International GmbH
- •Harminder Dua, Chair and Professor of Ophthalmology, University of Nottingham
- •lan Catchpole, Chief Scientific Officer, Horama
- •Brancine Behar-Cohen, Chief Innovation Officer, Eyevensys
- •Dr Thakur Raghu Raj Singh, Reader in Pharmaceutics, Queen's University Belfast

Highlights For 2020:

- •INSIGHT into the newest techniques in ocular drug design and delivery
- •EXPLORE the impacts and applications of controlled release technologies
- DEARN how advanced medical devices are changing the face of combined therapy
- UNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs

This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy

Registration is now open for interested parties at www.ophthalmicdrugs.com/pr1ein

Ophthalmic Drugs Conference 23rd-24th November 2020 Holiday Inn Kensington High Street, London, UK #OphthalmicDrugs

For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

---End---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We

create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu SMi Group +44 207 827 6088 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/520292526 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2020 IPD Group, Inc. All Right Reserved.